| Cat. No. |
Product Name |
Information |
| PC-20159 |
M4205
|
M4205 (IDRX-42) is a potent, highly selective inhibitor of KIT mutations with cell IC50 of 52 nM on cKIT autophosphorylation in the GIST430/654 cell line. |
| PC-35661 |
AZD3229
|
AZD3229 (AZD-3229) is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines (GI50=1-50 nM). |
| PC-62597 |
Famitinib
|
Famitinib (SHR1020) is a structural analogue of sunitinib, novel and potent multi-targeted RTK inhibitor, including c-Kit, VEGFR2/3, PDGFRβ, FLT-1/3 receptor and c-RET. |
| PC-62101 |
DCC-2618
|
DCC-2618 (Ripretinib) is a potent, oral inhibitor of singly and doubly mutated KIT with IC50 of WT (IC50=4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM), D816V. |
| PC-62100 |
Avapritinib
|
Avapritinib (BLU-285) is a potent and highly selective inhibitor of mutant KIT and PDGFRα with IC50 of 0.6, 0.27 and 0.24 nM for KIT del557-558, KIT D816V and PDGFRA D842V, respectively. |
| PC-45100 |
Sitravatinib
|
Sitravatinib (MGCD-516) is a broad spectrum small molecule inhibitor that blocks a wide array of RTKs known to be amplified/overexpressed in sarcomas, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl (IC50=1.5-30 nM). |
| PC-20030 |
BLU-263
|
Elenestinib (BLU-263, BLU263) is a potent, selective, oral next-generation KIT D816V inhibitor with IC50 of 0.2 nM. |
